Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Prognostic analysis of newly diagnosed systemic light-chain amyloidosis patients treated with daratumumab

View Full Paper
Ask AI
Bookmark
Share

Authors

YXYi XuCXChengyang XuAGAi Guan

Discussion

Loading...

Member takes

Overview

Analysis shows improved survival in AL patients treated with daratumumab, highlighting significant hematologic responses.

Key Points

  • Survival rates for patients treated with daratumumab indicate strong clinical outcomes and response over time.
  • At 3 months, complete response reached 43.1%, while overall response rate was 95.4% among 265 patients.
  • Analysis of hematologic responses and N-terminal pro–B-type natriuretic peptide levels illustrated significant patient outcomes.
  • These findings suggest daratumumab's effectiveness, but traditional markers like M-protein are less predictive now.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236de92https://doi.org/10.1182/blood-2025-2190
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab-based regimens in newly diagnosed mayo 2004 stage 3b AL amyloidosis: A systematic review2025
  2. 2Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy2025
  3. 3Real-world outcomes of daratumumab in light-chain amyloidosis patients with advanced renal failure: A TriNetX network study.2026
  4. 4Real-world outcomes of standard and modified daratumumab-based therapy in AL amyloidosis: A cohort study from a multidisciplinary program in south India2025
  5. 5Daratumumab in AL amyloidosis: survival, cardiac CR, and beyond2026